Why the study?
Does agomelatine improve symptoms of anxiety and depressive disorders safely in patients with ischemic heart disease?
Does agomelatine improve symptoms of anxiety and depressive disorders safely in patients with ischemic heart disease?
Agomelatine may be a viable option for treating depression and anxiety in patients with ischemic heart disease, though further studies are needed to establish its short- and long-term effects.
Agomelatine's role in IHD remains uncertain; leaves open the need for prospective trials on short- and long-term antidepressant effects.
According to the World Health Organization, anxiety and depressive disorders will be the second leading cause of disability by 2020. The review is devoted to the modern concepts of the pathophysiology of depression in patients with ischemic heart disease (IHD) and to the possibilities of antidepressant therapy. The paper presents analysis of international and domestic researches devoted to efficiency and safety of agomelatine in patients both with chronic IHD and with unstable angina and acute myocardial infarction. The review also discusses different points of view, indicating the need for further studies to evaluate the short and long term effects of antidepressants in patients with IHD in combination with anxiety and depressive disorders.
No takes yet. Share an insight, caveat, or question.
Shimohina et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: